Sanofi

SNY

NASDAQ

48.8

USD

+0.71(+1.48%)

As of today

Overview Financials Dividends Ratios Discussions Analysis

Sanofi fundamentals

Overview Income Statement Balance Sheet Cash Flow

Key ratios

P/E Ratio

16.27

Price/Book

1.47

Debt/Equity

31.83%

Return on Equity

12.39%

Dividend Yield

4.66%

EBITDA

11.03B

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Statements Highlights

AnnualQuarterly

Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024
Total Revenue	37,369,000,000	39,175,000,000	40,304,000,000	46,033,000,000	44,286,000,000
Gross Profit	25,212,000,000	26,920,000,000	28,679,000,000	31,797,000,000	31,081,000,000
Operating Income	14,113,000,000	8,126,000,000	13,149,000,000	12,980,000,000	14,450,000,000
Net Income	12,294,000,000	6,223,000,000	8,371,000,000	5,400,000,000	5,560,000,000
Total Assets	114,413,000,000	120,242,000,000	126,722,000,000	126,464,000,000	132,798,000,000
Total Current Liabilities	19,248,000,000	21,295,000,000	23,964,000,000	24,194,000,000	29,162,000,000
Total Equity	63,252,000,000	69,031,000,000	75,152,000,000	74,353,000,000	77,857,000,000
Free Cash Flow	5,335,000,000	8,479,000,000	8,325,000,000	8,639,000,000	5,886,000,000
Cash from Operations	7,449,000,000	10,522,000,000	10,526,000,000	10,258,000,000	9,081,000,000
Cash from Investing	3,588,000,000	-7,298,000,000	-2,075,000,000	-6,200,000,000	-4,407,000,000
Cash from Financing	-6,485,000,000	-7,056,000,000	-5,821,000,000	-8,052,000,000	-5,763,000,000
Net Change in Cash	4,488,000,000	-3,817,000,000	2,638,000,000	-4,026,000,000	-1,269,000,000

Sanofi

SNY

48.8

Sanofi fundamentals

Key ratios

Statements Highlights

Dividends

Analyst Recomendations